readthroughSign in
Nov 12, 2026Financing

Vor Bio expands RemeGen deal to add long-acting BAFF/APRIL drug RC298

Vor Bio amended its license with RemeGen to include RC298, paying $10 million cash plus warrants, with up to $300 million more tied to milestones.

Vor Bio announced on November 12, 2026 that it had amended and restated its existing license agreement with RemeGen Co., Ltd., adding a new drug candidate called RC298 to its existing BAFF/APRIL franchise built around telitacicept. The amended agreement was signed on November 11, 2026, according to the company's 8-K filing.

RC298 is described as an engineered TACI-Fc fusion protein designed to block both BAFF and APRIL, built to improve potency, pharmacokinetics, and manufacturability while allowing for sustained dual-pathway inhibition and longer intervals between doses.1 In preclinical testing, the company said RC298 showed stronger inhibition of BAFF and APRIL than existing inhibitors in the class, along with longer-lasting drug exposure in the body.1

On the financial terms, Vor Bio agreed to pay RemeGen roughly $56 million in total upfront value, made up of $10 million in cash plus pre-funded warrants for 2.3 million shares of Vor Bio stock at a nominal $0.0001 exercise price, with the warrant portion valued around $46 million based on the November 11 closing share price.1 RemeGen could also receive as much as $300 million tied to development milestones, with $20 million of that payable once certain early clinical and technology-transfer targets are met.1 The prior deal's framework for sales milestones and royalties will now apply across all the licensed products combined.1

RC298 is still in IND-enabling studies, and RemeGen expects to file for clearance to begin trials in China in the first half of 2027, with RemeGen running preclinical work and the Phase 1 trial there.1 Once Phase 1 is complete, Vor Bio will take over later-stage development, regulatory filings, and commercialization outside Greater China.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.